Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib. [electronic resource]
Producer: 20060612Description: ECR36 p. digitalISSN:- 1592-8721
- Adult
- Antimetabolites, Antineoplastic -- therapeutic use
- Antineoplastic Agents -- pharmacology
- Benzamides
- Combined Modality Therapy
- Cytarabine -- therapeutic use
- Drug Resistance, Neoplasm
- Fusion Proteins, bcr-abl -- antagonists & inhibitors
- Granulocyte Colony-Stimulating Factor -- pharmacology
- Hematopoietic Stem Cell Mobilization
- Humans
- Imatinib Mesylate
- Interferons -- therapeutic use
- Lenograstim
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Leukemia, Myeloid, Chronic-Phase -- drug therapy
- Male
- Peripheral Blood Stem Cell Transplantation
- Piperazines -- pharmacology
- Pyrimidines -- pharmacology
- Recombinant Proteins -- pharmacology
- Remission Induction
- Transplantation, Autologous
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.